{"id":39741,"date":"2025-08-20T13:01:36","date_gmt":"2025-08-20T05:01:36","guid":{"rendered":"https:\/\/flcube.com\/?p=39741"},"modified":"2025-08-20T13:01:37","modified_gmt":"2025-08-20T05:01:37","slug":"hansohs-ameile-fuels-revenue-growth-to-rmb-7-434-billion-in-h1-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39741","title":{"rendered":"Hansoh&#8217;s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025"},"content":{"rendered":"\n<p>China-based Hansoh Pharmaceutical Group Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&amp;D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.<\/p>\n\n\n\n<p><strong>Ameile&#8217;s Market Expansion<\/strong><br>Revenue from oncology products, including the innovative drug Ameile (Aumolertinib Mesilate Tablets), reached approximately RMB 4.531 billion, or 60.9% of total revenue. As China&#8217;s first original third-generation EGFR-TKI drug, Ameile continues to expand its therapeutic potential in lung cancer treatment, with four indications approved in China. In May 2025, it was approved for treating adult patients with stage II to IIIB non-small cell lung cancer (NSCLC). In June 2025, Ameile, marketed as Aumseqa in the UK, received marketing authorization from the UK&#8217;s Medicines and Healthcare products Regulatory Agency (MHRA).<\/p>\n\n\n\n<p><strong>Pipeline Momentum<\/strong><br>Hansoh expanded its innovative drug pipeline with over 70 ongoing clinical trials, covering more than 40 drug candidates. Notable additions included phase 3 pivotal registration trials for HS-20093, a B7-H3-targeted ADC for bone and soft tissue sarcoma; HS-20089, a B7-H4-targeted ADC for ovarian cancer; and HS-20137, an IL-23p19 monoclonal antibody. Additionally, eight new drug candidates, including two ADCs, were approved for clinical trials, underscoring the company&#8217;s commitment to innovation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/H2_AN202508181729888980_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202508181729888980_1.\"><\/object><a id=\"wp-block-file--media-dac89fd6-0e30-4100-9600-05cbd2b991bc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/H2_AN202508181729888980_1.pdf\">H2_AN202508181729888980_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/H2_AN202508181729888980_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dac89fd6-0e30-4100-9600-05cbd2b991bc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39744,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,27,363,1182],"class_list":["post-39741","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biotech","tag-finanical-reports","tag-hansoh-pharmaceutical","tag-hkg-3692"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh&#039;s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&amp;D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39741\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh&#039;s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025\" \/>\n<meta property=\"og:description\" content=\"China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&amp;D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39741\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T05:01:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-20T05:01:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2006.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh&#8217;s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025\",\"datePublished\":\"2025-08-20T05:01:36+00:00\",\"dateModified\":\"2025-08-20T05:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2006.webp\",\"keywords\":[\"Biotech\",\"Finanical Reports\",\"Hansoh Pharmaceutical\",\"HKG: 3692\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39741#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39741\",\"name\":\"Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2006.webp\",\"datePublished\":\"2025-08-20T05:01:36+00:00\",\"dateModified\":\"2025-08-20T05:01:37+00:00\",\"description\":\"China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39741\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2006.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2006.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39741#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh&#8217;s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39741","og_locale":"en_US","og_type":"article","og_title":"Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025","og_description":"China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.","og_url":"https:\/\/flcube.com\/?p=39741","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-20T05:01:36+00:00","article_modified_time":"2025-08-20T05:01:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2006.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39741#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39741"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh&#8217;s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025","datePublished":"2025-08-20T05:01:36+00:00","dateModified":"2025-08-20T05:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39741"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39741#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2006.webp","keywords":["Biotech","Finanical Reports","Hansoh Pharmaceutical","HKG: 3692"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39741#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39741","url":"https:\/\/flcube.com\/?p=39741","name":"Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39741#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39741#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2006.webp","datePublished":"2025-08-20T05:01:36+00:00","dateModified":"2025-08-20T05:01:37+00:00","description":"China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39741#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39741"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39741#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2006.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2006.webp","width":1080,"height":608,"caption":"Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39741#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh&#8217;s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2006.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39741"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39741\/revisions"}],"predecessor-version":[{"id":39745,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39741\/revisions\/39745"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39744"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}